Last updated: September 4, 2026
The hydrocortisone, neomycin sulfate, and polymyxin B sulfate combination is a mature, multisource topical anti-infective and corticosteroid market. Its commercial value is distributed across otic, ophthalmic, dermatologic, cream, ointment, and solution products rather than concentrated in one protected brand. Patent-driven pricing power is minimal, FDA exclusivity has expired, biosimilar risk is irrelevant, and future revenue depends mainly on prescription volume, reimbursement, manufacturing reliability, and product availability.
Public filings do not report consolidated revenue for the active-ingredient combination. The financial trajectory is therefore best evaluated through product maturity, generic competition, channel economics, and the position of branded products such as Cortisporin and Neo-Poly-HC.
What drugs contain hydrocortisone, neomycin sulfate, and polymyxin B sulfate?
The combination is used in products that pair hydrocortisone with the antibiotics neomycin and polymyxin B. The dosage form determines the market, regulatory label, and competitive set.
| Product category |
Typical dosage forms |
Primary use |
Commercial characteristics |
| Otic products |
Solution, suspension, ointment |
Bacterial external-ear infections with inflammation |
Established generic market; often prescribed for short courses |
| Ophthalmic products |
Ointment, suspension, solution |
Selected bacterial eye infections with inflammatory symptoms |
More stringent manufacturing and sterility requirements |
| Dermatologic products |
Cream, ointment |
Infected or inflamed superficial skin conditions |
Competes with numerous topical antibiotics and corticosteroids |
| Combination prescription products |
Branded or authorized generic |
Anti-infective and anti-inflammatory treatment |
Brand value is limited by old active ingredients and generic substitution |
Cortisporin-branded products have historically represented the best-known commercial expression of the combination in otic and ophthalmic markets. Similar formulations are also sold under generic labels and private-label distribution arrangements. Product names and availability vary by dosage form and jurisdiction.
The combination should not be confused with products containing hydrocortisone and antibiotic ingredients but omitting polymyxin B, or with ophthalmic products containing dexamethasone instead of hydrocortisone. These products occupy adjacent but distinct markets.
What is the FDA regulatory status of the combination?
The combination is regulated as a prescription drug in the United States for the principal otic and ophthalmic products. It is not a biologic and does not follow the biosimilar pathway.
FDA labeling for Cortisporin Otic products identifies hydrocortisone, neomycin sulfate, and polymyxin B sulfate as active ingredients and describes treatment of superficial bacterial infections of the external auditory canal with inflammatory manifestations.[1] FDA labeling for ophthalmic products applies the same pharmacologic concept to selected eye infections but includes stronger warnings concerning ocular use, hypersensitivity, prolonged use, and potential steroid-related complications.[2]
FDA exclusivity status
The active ingredients have been used in prescription products for decades. New-drug exclusivity periods have expired, and the combination does not have a current market position based on orphan exclusivity, pediatric exclusivity, or a newly approved active ingredient.
The commercial implications are direct:
- Generic approval is available through abbreviated new drug applications where the relevant reference product and dosage form support an ANDA pathway.
- Manufacturers compete primarily on price, supply reliability, distribution, and formulary position.
- Product-specific exclusivity can still arise from a newly approved formulation or a limited regulatory designation, but it does not protect the established combination as a whole.
- No biosimilar exclusivity applies because the products are small-molecule drugs, not biological products.
What patents protect hydrocortisone, neomycin, and polymyxin B products?
The core active-ingredient combination is not protected by a modern composition-of-matter patent estate. Any historical patents covering the active substances, basic combinations, or conventional dosage forms have expired.
Patent protection may still arise around a particular formulation, delivery system, manufacturing process, container, or preservative system. Those rights are separate from protection for the active ingredients.
| Potential IP layer |
Relevance to this combination |
Expected commercial effect |
| Active ingredients |
Historical patents expired |
No current composition barrier |
| Conventional otic solution or suspension |
Generally mature technology |
Limited ability to sustain premium pricing |
| Ophthalmic sterile formulation |
Manufacturing know-how and process controls matter |
Can raise entry costs without creating broad exclusivity |
| Preservative system |
May support formulation claims |
Usually narrow and avoidable |
| Packaging and delivery device |
May cover droppers, tubes, or applicators |
Product-specific protection |
| Method of use |
May cover a defined infection or dosing method |
Narrow clinical scope; substitutable in routine practice |
| Manufacturing process |
May protect production parameters |
Can be designed around; rarely blocks the market |
How strong is the patent estate?
The patent estate is weak for the conventional combination. The main barriers are regulatory quality requirements, sterile manufacturing, validated filling systems, supplier qualification, and commercial scale. These barriers can reduce the number of reliable suppliers, but they do not create the pricing power associated with an active patent estate.
For generic manufacturers, the more relevant risks are formulation equivalence, preservative compatibility, particulate control, sterility assurance, container closure integrity, and stability. Those issues can delay approval or trigger supply interruptions without extending exclusivity.
When does hydrocortisone, neomycin, and polymyxin B lose exclusivity?
The combination has already lost primary market exclusivity in the United States. The relevant commercial question is not an upcoming loss date but the extent of residual brand loyalty and the number of approved or commercially active suppliers.
FDA’s Orange Book identifies patents and regulatory exclusivity associated with approved listed drugs. Mature products may have few or no current Orange Book patents, particularly where the commercial reference product is an old formulation and generic competition is established.[3]
Patent expiration dates
A single expiration date cannot be assigned to the combination because protection depends on the specific product, formulation, and jurisdiction. The active ingredients themselves do not provide a live patent barrier. Any remaining patent claim would need to be assessed against the exact product and dosage form.
The practical timeline is:
| Period |
Market status |
| Historical development period |
Original active-ingredient and formulation rights may have applied |
| Generic-entry period |
ANDA and equivalent national procedures become available |
| Current market |
Mature, multisource, price-sensitive market |
| Future outlook |
Incremental reformulations may create narrow, product-specific rights |
Are there Paragraph IV challenges to these products?
Paragraph IV litigation is not the principal competitive mechanism for the established combination. Paragraph IV certifications matter when an ANDA applicant challenges an Orange Book-listed patent. For old hydrocortisone, neomycin, and polymyxin B products, the more common commercial pattern is approval and substitution in a mature market rather than a major patent contest.
A Paragraph IV filing could still occur against a listed formulation patent, but the economic value of such litigation would generally be limited unless the challenged product had substantial volume, a differentiated delivery system, or a premium branded position.
No major, current, product-defining Paragraph IV dispute is evident from the public regulatory profile of the conventional combination. Litigation exposure is therefore lower than for recently approved small-molecule products with active formulation or method-of-use patents.
What patent litigation affects the market?
The principal litigation risks are product-specific rather than ingredient-wide.
Formulation and manufacturing disputes
Potential disputes may involve:
- Whether a generic product is pharmaceutically equivalent to the reference product.
- Suspension particle size and uniformity.
- Sterility and preservative systems in ophthalmic products.
- Container closure and delivery performance.
- Labeling for steroid-containing products.
- Process patents covering filling, mixing, or stabilization.
These claims are generally narrower than composition patents. A competing manufacturer may design around them by changing excipients, packaging, manufacturing conditions, or labeling.
Method-of-use patents
Method-of-use patents could address treatment of a defined infection, dosing schedule, or patient population. Their value is constrained by the broad historical use of the ingredients and the availability of alternative antibiotic-steroid products.
For generic substitution, the key regulatory issue is whether the proposed label and any permissible carve-outs avoid an infringing use while retaining approval for nonprotected indications. This issue is more important for newer products than for the conventional hydrocortisone combination.
Settlement agreements
There is no widely recognized, market-defining settlement agreement controlling generic entry for the conventional combination. Any private settlement would need to be evaluated at the product and patent level because it would not automatically govern every dosage form or jurisdiction.
How large is the market for hydrocortisone, neomycin, and polymyxin B?
The market is fragmented and relatively small compared with major chronic-care pharmaceuticals. Demand comes from episodic treatment of ear, eye, and skin conditions. Prescription volume is influenced by primary care, pediatrics, otolaryngology, ophthalmology, dermatology, urgent care, and emergency settings.
The market has several structural characteristics:
- Treatment courses are generally short, limiting recurring revenue per patient.
- Generic substitution is common where an equivalent product is available.
- Products are often purchased through wholesalers, retail pharmacies, health systems, and group purchasing organizations.
- Otic and dermatologic products are easier to manufacture than sterile ophthalmic products.
- Ophthalmic products can command higher unit economics but have greater quality and compliance requirements.
- Prescribing is affected by concerns about neomycin hypersensitivity and inappropriate steroid use.
The combination competes with:
- Antibiotic-only otic products.
- Fluoroquinolone otic products.
- Other antibiotic-corticosteroid combinations.
- Nonprescription topical antibiotic products in dermatology.
- Newer ophthalmic antibiotic-steroid products.
- Generic hydrocortisone products used separately from topical antibiotics.
What is the financial trajectory for these products?
The financial trajectory is mature to declining in nominal terms for undifferentiated products, with periodic price increases caused by supply disruptions rather than durable demand expansion.
| Financial driver |
Direction |
Effect on revenue |
| Patient volume |
Stable to modestly declining |
Limits organic growth |
| Generic competition |
High |
Compresses average selling price |
| Brand recognition |
Moderate for legacy brands |
Supports selected premium products |
| Short treatment duration |
Structural constraint |
Low lifetime value per patient |
| Ophthalmic manufacturing complexity |
Supports supplier discipline |
Can protect margins for reliable producers |
| Supply shortages |
Volatile |
May temporarily increase pricing and market share |
| Reimbursement pressure |
Negative |
Reduces realized net price |
| New indication growth |
Limited |
Few obvious expansion opportunities |
Public company filings generally do not disclose revenue for the specific active-ingredient combination. Revenue may be aggregated within a dermatology, ophthalmology, hospital-products, or legacy-brand portfolio. As a result, product-level financial modeling should use prescription volume, channel price, manufacturer count, and dosage-form mix rather than reported corporate revenue.
Revenue exposure for manufacturers
Revenue exposure is asymmetric:
- A diversified generic manufacturer typically has low exposure to one combination but may benefit from portfolio scale.
- A specialty company with a recognized otic or ophthalmic brand may have meaningful exposure despite modest absolute sales.
- Contract manufacturers can capture value through supply agreements even when the product owner has limited pricing power.
- Distributors benefit from volume and availability but face low product-level margins.
- A manufacturer with a reliable sterile ophthalmic line may achieve better economics than a company selling commodity dermatologic cream.
The greatest financial risk is a manufacturing interruption. In a mature generic market, a supplier that loses approval, encounters contamination, or exits the product can create temporary scarcity and price increases. Those gains are usually unstable because other suppliers can enter or expand production.
Which companies are challenging the market?
Competition is likely to come from several categories rather than a single named challenger:
- Generic manufacturers with ANDA-approved products.
- Specialty pharmaceutical companies marketing branded otic or ophthalmic products.
- Contract development and manufacturing organizations.
- Private-label suppliers serving pharmacy and hospital channels.
- Manufacturers of alternative antibiotic-steroid combinations.
The market’s competitive structure changes by dosage form. Otic solutions and suspensions tend to have more direct generic substitution. Ophthalmic ointments and suspensions have higher technical barriers because of sterility and product-performance requirements. Dermatologic formulations face the broadest competition from both prescription and nonprescription products.
What generic launch scenarios exist?
Scenario 1: Continued commodity erosion
This is the base case for standard products. Multiple suppliers maintain approval, payers prefer low-cost alternatives, and average selling prices decline gradually. Brand products retain only a limited premium based on availability, prescriber familiarity, or distribution.
Scenario 2: Supplier consolidation
If manufacturers exit because of low margins, the remaining suppliers gain temporary volume and pricing leverage. This can improve revenue per unit but raises regulatory and supply-chain concentration risk.
Scenario 3: Sterile ophthalmic shortage
A quality event or manufacturing shutdown can produce short-term scarcity in ophthalmic products. Suppliers with validated sterile capacity may gain market share. Revenue can rise quickly, but the benefit depends on FDA enforcement, competing approvals, and restoration of supply.
Scenario 4: Reformulated or device-enabled product
A company could seek differentiation through a preservative-free formulation, improved delivery system, longer shelf life, or a more convenient package. Such products may obtain limited formulation protection and higher pricing, but they would compete against low-cost conventional products.
What geographic coverage does the market have?
The active ingredients have broad global use, but regulatory and commercial conditions vary.
| Region |
Market characteristics |
| United States |
Mature prescription market; ANDA competition; Orange Book relevance |
| European Union |
National reimbursement and decentralized commercial access; brand and generic competition vary by country |
| Canada |
Provincial reimbursement and generic substitution; product availability differs by province |
| Latin America |
Mix of prescription, pharmacy, and branded-generic channels |
| Asia-Pacific |
Large manufacturing base; wide variation in regulatory standards and retail access |
| Emerging markets |
Greater price sensitivity and more variable quality oversight |
A U.S. product may not have a direct commercial equivalent in Europe or Asia because of differences in preservative systems, dosage forms, labeling, and regulatory classification. Geographic expansion is therefore more dependent on registration and distribution than on patent clearance.
What manufacturing and intellectual-property barriers exist?
The strongest barriers are operational.
For otic and dermatologic products, manufacturing is relatively established. The principal requirements are raw-material quality, content uniformity, microbiological control, stability, and validated packaging.
Ophthalmic products require more demanding controls:
- Sterile manufacturing and aseptic processing.
- Endotoxin and particulate testing.
- Container closure integrity.
- Preservative effectiveness where applicable.
- Consistent delivery from the package.
- Stability throughout the labeled shelf life.
- Controls for cross-contamination and microbial ingress.
Neomycin also creates a safety and labeling issue because sensitization can occur. Hydrocortisone creates additional restrictions concerning prolonged use, ocular pressure, delayed healing, and masking of infection. These risks affect prescribing and pharmacovigilance but do not create meaningful exclusivity.
How does this combination compare with newer antibiotic-steroid products?
| Attribute |
Hydrocortisone/neomycin/polymyxin B |
Newer antibiotic-steroid products |
| Patent position |
Generally expired |
May have active formulation or use patents |
| Generic competition |
Established |
Often limited during exclusivity |
| Price |
Low to moderate |
Higher where brand protected |
| Clinical familiarity |
High |
Varies |
| Hypersensitivity concern |
Neomycin-related risk |
Depends on antibiotic |
| Manufacturing complexity |
Highest for ophthalmic forms |
Often high for sterile products |
| Revenue growth |
Limited |
Can grow during launch and exclusivity |
| Litigation risk |
Usually low |
Higher if Orange Book patents are listed |
The combination remains commercially relevant because of familiarity, availability, and low cost. It does not have the growth profile of a recently launched branded anti-infective or specialty therapy.
Key Takeaways
- Hydrocortisone, neomycin sulfate, and polymyxin B sulfate products are mature prescription medicines with broad generic competition.
- The core active-ingredient combination has no meaningful current composition-of-matter exclusivity.
- Patent risk is product-specific and may involve formulations, delivery devices, manufacturing methods, or narrow methods of use.
- No biosimilar risk applies because these are small-molecule drugs.
- Paragraph IV litigation is not the central market driver for conventional products.
- Revenue is likely stable to declining for undifferentiated products, with temporary increases during supply shortages.
- Ophthalmic products have stronger manufacturing barriers and potentially better margins than standard otic or dermatologic products.
- Product-level revenue is generally not disclosed in public company filings, so financial analysis requires volume, price, channel, and supplier data.
- The main investment variables are generic intensity, supplier concentration, sterile manufacturing capacity, reimbursement, and brand retention.
FAQs
Is hydrocortisone, neomycin, and polymyxin B still commercially important?
Yes, but primarily as a mature generic and legacy-brand product family. Its importance is based on prescription volume and clinical familiarity, not exclusivity.
Can a company obtain new patents on this old drug combination?
Yes. A company may pursue patents on a new formulation, preservative system, delivery device, manufacturing process, or narrowly defined use. Such patents would not automatically protect conventional versions of the combination.
Are hydrocortisone, neomycin, and polymyxin B products subject to biosimilar competition?
No. The ingredients are small-molecule drugs. Competition occurs through generic drug applications and branded-generic products rather than biosimilar applications.
Why can an old generic product experience price increases?
Manufacturing disruptions, supplier exits, quality recalls, raw-material shortages, or limited sterile capacity can reduce supply. A temporary shortage may increase prices until production resumes or another supplier expands.
Which dosage form has the strongest commercial economics?
Ophthalmic products can have better unit economics because sterile manufacturing limits the supplier pool. They also carry greater compliance, quality, and liability exposure. Otic and dermatologic products have lower technical barriers and generally face stronger price competition.
References
-
U.S. Food and Drug Administration. (n.d.). Cortisporin otic solution: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Hydrocortisone, neomycin sulfate, and polymyxin B sulfate ophthalmic products: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and generic drug information. https://www.fda.gov/drugs/generic-drugs
